Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
The US Food and Drug Administration (FDA) has approved Amgen's Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) for the treatment of specific rare diseases.
Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its planned Stelara biosim rollout in 2025. But thanks to a new FDA approval ...
Pharmaceutical regulators approved Amgen's (AMGN) Bkemv, a biosimilar to rare-disease treatment Soliris. The Food and Drug Administration said Tuesday that Bkemv, a monoclonal antibody, had been ...
A panel of experts advising the Food and Drug Administration could on Monday recommend Eli Lilly’s experimental Alzheimer’s ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
There isn’t a cure for Alzheimer’s disease, the most common form of dementia in the U.S., but a third treatment for the ...
A U.S. Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug ...
The FDA's vaccine advisory panel voted to recommend that this fall’s Covid-19 shots should be updated to target Omicron’s ...
The new weight-loss drug company emerged from stealth with big plans to take on obesity drugs like Wegovy and Zepbound.
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...